Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Filter life time of continuous renal replacement therapy
研究概览
简要总结
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy
排除标准
- •Age < 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study
结局指标
主要结局
Filter life time of continuous renal replacement therapy
时间窗: Individual time point, standardized
Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.
次要结局
- Activation of coagulation(beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis)
研究者
Klinik für Anästhesiologie
Leiter Interdisziplinäre Operative Intensivstation ZOM-I
Heinrich-Heine University, Duesseldorf